Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases October 2, 2017 Parexel International Taps New CEO Jamie Macdonald March 5, 2018 <b>CROS NT</b> Launches CROScheck At DIA Chicago To Help Clinical Trial Sponsors Meet New ICH GCP E6(R2) Guidelines June 22, 2017
Celgene Cuddles Up With Another Cambridge Biotech, This Time to Tackle Autoimmune Diseases October 2, 2017
<b>CROS NT</b> Launches CROScheck At DIA Chicago To Help Clinical Trial Sponsors Meet New ICH GCP E6(R2) Guidelines June 22, 2017
